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ABSTRACT
Clinical microbiologists and microbiology laboratories are experiencing changes due to evolving views
on ‘healthcare delivery’ as an economic activity, due to changes in the medical environment and the
demographics of the workforce, and technical evolution. Cost-effectiveness of laboratory procedures
has been achieved through consolidation and integration of laboratories. Consolidation offers
economy of scale and reduction in numbers of on-site staff, but also leads to separation of
microbiologists from their clinical colleagues. Integration puts different laboratory disciplines under a
single management, and leads to reorganisation of laboratories along common work-lines. Cost-
savings combined with on-site availability of laboratories are achieved at the expense of a reduction in
the inﬂuence of microbiologists in the daily running of the laboratory. Medically, there is growing
emphasis on evidence-based diagnostics. Because of time-delays inherent in culturing, microbiology
has a limited impact on patient outcomes. Increased clinical relevance of microbiological testing
through rapid testing is mandatory. There is an increasing shortage in Europe and the USA of trained
microbiology laboratory technicians and microbiologists. This reinforces the trend towards more
automation and integration. Technological advances, particularly in molecular diagnostics, offer the
possibility of rapid reporting and improvement of the impact of clinical microbiology on patient
management. Molecular tests, however, ﬁt perfectly the concept of an integrated laboratory and may
further loosen the link between microbiologist and microbiology tests. The challenge for clinical
microbiology will be to use new techniques to improve its cost-effectiveness and impact on infectious
disease management. The future organisation of microbiology laboratories must support this but is
itself of secondary importance. The training of future microbiologists must prepare them for this
changing environment.
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INTRODUCTION
Many factors will have an impact on the future
development and daily practice of clinical micro-
biology. These factors can be roughly subdivi-
ded into four overlapping categories: the
changing economic environment, changes in
the demographics of the workforce, the chan-
ging medical environment, and technological
advances.
THE ECONOMIC ENVIRONMENT
There is a clear tendency to move away from the
fee-for-service type of medicine to a managed-care
type of medicine that tries to optimise the cost-
efﬁcient use of the available resources. This evolu-
tion will also impact on the organisation of clinical
microbiology laboratories. Two kinds of response
are already clearly visible. The ﬁrst is the consol-
idation of separate laboratories into bigger entities
via mergers, acquisition of smaller laboratories by
large laboratories, or the formation of networks. A
second possible response is to streamline different
sub-specialty laboratories into uniﬁed and integ-
rated large-scale laboratories.
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In a 1998 American Society for microbiology
(ASM) survey [1], 33% of 351 survey respondents
acquired another institution, 26% merged with
another institution, and 50% reported increased
partnerships or afﬁliations with other laboratories.
Similar changes are taking place in Europe. There
are, of course, clear advantages to consolidation.
There is, for example, the removal of tests to
(off-site) central laboratories. Particularly expen-
sive and rare tests that do not demand short
turn-around times are relegated to such central
laboratories. This will, of course, lead to an econ-
omy of scale and reduction in staff numbers, and
might even improve the quality of testing. On the
other hand, it will also lead to a physical separation
of supervisory staff from the clinical services and
clinicians with whom they are working.
Integration implies a reorganisation of laborat-
ory workﬂow based on common processes and
technologies. Usually, there is a core laboratory
that contains the large automated equipment
which is surrounded by satellite laboratories
speciﬁcally concentrating on, for example, immu-
noassays, molecular techniques, microbiological
cultures, haematology, or special chemistry. The
core laboratory offers the advantage of concentra-
ting highly automated, cross-capable instrumen-
tation with a 24-h service. Streamlining of work
processes into core and satellite laboratories
implies training of technicians according to com-
mon techniques as opposed to medical sub-spec-
ialties. In our own laboratories (University
Hospital Leuven, Belgium), integration of many
different small and large sub-specialty laborator-
ies into a single service was accomplished several
years ago. The former independent laboratories of
clinical chemistry, hormonology, bacteriology,
virology, immunology and haematology were
re-localised in a single custom-designed laborat-
ory space, and all activities were reorganised into
so-called production teams. These production
teams are organised around the use of common
techniques or instruments rather than medical
sub-specialties. We have a core laboratory
(so-called production team 1) that is organised
around the large automated equipment and pro-
duction teams for semi-automated and manual
immunoassays, specialised chemistry, bacterial
cultures and molecular diagnostics. Financial con-
straints have certainly been important in this
reorganisation. The advantages of the integrated
laboratory have been self-evident. They are the
economy of scale, shorter turn-around times for
many tests, standardisation of quality, and higher
throughput. The economy of scale that comes from
using common platforms and technicians speci-
ﬁcally trained for molecular diagnostics has, for
example, made it possible to double the number of
molecular tests without increasing the number of
laboratory technicians, thus almost halving the
cost per test. However, there are also disadvanta-
ges of integration. It might lead to a loss of speciﬁc
(microbiological) expertise because of the
increased cross-training and trans-sub-specialty
use of technicians. Another potential problem is
that the disappearance of medical sub-specialty
laboratories induces a sense of loss of identity and
purpose in many microbiologists, not least
because their responsibilities in the actual running
of the laboratory are reduced. Microbiology as
such plays only a minor role within the totality of
laboratory diagnostic services. For example, in
Europe as a whole, microbiology occupies only
5% of the in-vitro diagnostics market in ﬁnancial
terms [2]. As a consequence, in integrated and in
consolidated laboratories, the majority of micro-
biologists who experienced changes judged that
their decision-making authority declined [1].
It is not surprising that some predict that the
integration of microbiology into an integrated
laboratory structure may augur the end of the
traditional hospital-based microbiology laborat-
ory as a physical entity. However, it will not
eliminate the need for clinical microbiologists. In
this new organisation, microbiologists must rede-
ﬁne their functions and tasks more at the level of
the medical interface than in the day-to-day
running of the laboratory [3].
THE WORKFORCE
A second factor that is often underestimated, but
will also have an impact on the way in which
clinical microbiology will develop in the coming
years, is the availability of a trained workforce.
Age distribution data available in a few European
countries suggest that in many countries, a large
part of the medical microbiology technician
workforce will retire in the next 10–15 years.
There are already shortages of technicians in
many laboratories, particularly in the ﬁeld of
microbiology, with its need for highly trained
technicians. In Belgium, the majority of microbio-
logical medical laboratory technicians are in the
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age group 45–55 years, and therefore due to retire
within the next 10–15 years [4]. There are not
sufﬁcient newcomers to ﬁll these vacancies, and
there is a declining interest in the training of
medical laboratory technicians. In the USA, it is
predicted that in each of the next 10 years a
shortfall of c. 4400 workers per year will occur [5].
Of 86 medical microbiology laboratories inter-
viewed in the USA, 31% reported no vacancies;
37% of the available positions had been unﬁlled
for more than 6 months [6]. This trend can only
increase in the coming years.
It could be that the trend towards increasing
automation will reduce the need for highly
trained microbiological staff. Thus, technicians
with less training could comprise a larger part of
the medical microbiology workforce. It is a matter
of debate whether this will have an impact on the
quality of the service. The introduction of, for
example, molecular techniques, with their poten-
tial for miniaturisation and automation, will only
strengthen this trend.
Shortages are not only imminent at the level of
technicians; the same shortage is also apparent at
the level of microbiologists. In Belgium, more than
half of the microbiologists are in the age group
45–55 years [4]. Similar data come, for example,
from Sweden and The Netherlands, with docu-
mented shortages of microbiologists in the near
future [7,8]. Together, these data reveal an addi-
tional factor that might impact on the develop-
ment of clinical microbiology and might reinforce
the trend towards more automation and integra-
tion in order to maximise the efﬁcient use of a
(reduced) available workforce. These observations
strengthen the need to clearly deﬁne the function
of the microbiology technician and medical micro-
biologists in such a way that a sufﬁcient number of
good people will continue to be attracted.
THE MEDICAL ENVIRONMENT
The change in the medical environment is partic-
ularly apparent in the increasing emphasis on
evidence-basedmedicine and theuseof guidelines.
This trend is not speciﬁc to medicine but is
apparent in all aspects of human activity. The
emphasis on evidence-based diagnostics and the
proven impact of diagnostic interventions
onpatientoutcomewill alsoput furtherpressureon
clinical microbiology to prove its cost-effective-
ness. The importance attributed to cost and
cost-effectiveness is apparent from the number of
publications dealing with this subject. A quick
search ofMedline shows that the number of papers
that included the search term ‘cost’ or ‘cost effect-
iveness’ in conjunctionwith ‘clinicalmicrobiology’
almost doubled from six per 1000 at the beginning
of the 1990s to 12 per 1000 at the end of the 1990s.
Unfortunately, the real impact of clinical micro-
biology on the acute management of infectious
diseases is a matter of dispute. Several facts
illustrate this statement. Although the majority of
antibiotics are prescribed in the outpatient setting,
microbiological testing in the community setting
is very limited. Even more worrisome, for exam-
ple, are data from Belgium that show that even in
the hospital setting, microbiological analyses are
only performed in approximately 60% of patients
who are treated with antibiotics because of an
infection [9]. When a result is eventually returned
from the laboratory to the clinician, several
studies from 1981 onwards document with some-
what surprising unanimity that in only half of the
cases are these results known or used by clini-
cians [10–12]. Recent publications and guidelines
on the diagnosis and treatment of serious infec-
tions such as pneumonia (community-acquired
and hospital-acquired) or intra-abdominal infec-
tions all indicate that the initial and adequate
antibiotic treatment is the most important prog-
nostic factor. Identifying the microbial cause of
the infection may aid in clinical management, but,
to date, there are few data showing that aetiolo-
gical diagnostic testing can improve outcomes or
reduce overall medical costs [13,14].
This controversy will continue and will put
increasing pressure on clinical microbiology
laboratories until rapid and accurate tests become
available and have proven cost-effectiveness in
the management of infectious diseases.
THE TECHNOLOGICAL CONTEXT
The specialised press, as well as ﬁnancial analysts,
expect molecular genetic diagnostics to be a real
growth market in the coming years. The greatest
threat to this growth scenario is the, so far,
very limited reimbursement for these expensive
tests. Nevertheless, large pharmaceutical and
diagnostic ﬁrms continue to invest in molecular
testing. They believe that molecular diagnostics
will play an increasing role in the marketing and
development of new drugs and that they will lead
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to more synergy between diagnostics and ther-
apy. Molecular diagnostics will facilitate identiﬁ-
cation of persons at risk, will allow early detection
of asymptomatic disease, and will allow
monitoring of treatment and thus pave the way
for new drugs for early stages, for prophylactic
drugs, for the more efﬁcient use of existing drugs,
and for new drugs for non-responders. Added to
this are the public awareness of molecular testing
and the public perception of molecular genetic
tests as the most advanced and reliable kind of
test. These forces will, in the coming years, drive
the further development of molecular tests.
As regards clinical microbiology, we must
consider the impact of these molecular tests on
the evolution of the laboratory ‘landscape’.
Molecular diagnostics ﬁt very nicely into the
concept of consolidation, integration and automa-
tion. They ﬁt very nicely into the evolution
towards technology-based specialty laboratories
and might thus contribute to the decline of the
classic microbiology laboratory, which centralised
all the microbiological testing, irrespective of the
technology used.
But can clinical microbiology afford not to
invest in molecular diagnostics?
Molecular diagnostics, with their promise of
short turn-around times and their potential for
more detailed genotypic analysis of the causative
pathogen, have the potential to increase the
impact of clinical microbiology on infectious
disease management. Even though it is certainly
true that there are still many problems with
molecular tests in infectious disease management,
such as determination of antibiotic susceptibility
or even the clinical interpretation of quantitative
PCR, the possibility of rapid testing offered by
molecular tests is very important for the long-
term cost-effectiveness of clinical microbiology.
CONCLUSION
Clinical microbiology must adapt to the new
healthcare environment. In this context, it is
important to monitor and evaluate the factors
affecting clinical microbiology laboratories. Do we
have an idea of the changing economic and
workforce environment in Europe and do we
know what the impact of these changes will be?
We must also reﬂect on the changes that are
already taking place in clinical microbiology
laboratories. Is the consolidated ⁄ integrated
laboratory a valuable model for microbiological
laboratories in Europe? What is the role of the
microbiologist in a consolidated ⁄ integrated labor-
atory andmust we prepare microbiologists for this
role? How can we exploit the potential of molecu-
lar genetic diagnostics to increase the impact of
microbiology on infectious disease management?
There is no doubt that the primary objective of
clinical microbiology is to improve infectious
disease management. In order to increase the
cost-effectiveness of clinical microbiology, we
must invest in more rapid testing and evaluate
tests in terms of patient outcome. The organisa-
tion of the microbiology laboratory must support
this objective, even if this implies that microbiol-
ogists would lose part of their responsibility in the
daily running of the laboratory.
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